

## Update for the Quarter Ending 31 December 2019

**Brisbane, Australia, 31 January 2020** – ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to provide an update on the company's activities for the second quarter ended December 31, 2019.

Tony Keating, CEO and Managing Director commented on the quarter: "With key regulatory approvals in Australia and Europe secured, much of the quarter was spent laying the groundwork for successful commercialisation. We are building a strong commercial pipeline and our partnership with CoviU represents a major opportunity to integrate our unique technology into Australia's largest telehealth platform. We continue to engage with and receive very positive feedback from hospital emergency departments, telehealth organisations and other healthcare companies globally; and we expect these discussions to convert into formal agreements in the coming months. We are also excited by the progress we've made with Sanofi on a consumer-facing respiratory disease product during the Startup Creosphere program and are now looking forward to the next step in that project."

### Recent Highlights and Outlook

- **Continued progress on global regulatory approvals.** During the second quarter, ResAppDx-EU received Australian Therapeutic Goods Administration (TGA) approval for paediatric use. The company has submitted an application to the TGA for adult use with the CE Mark as Manufacturer's Evidence. The TGA are waiting for an updated CE Mark certificate with ResApp's new office address to be issued by ResApp's notified body. ResApp's De Novo submission for paediatric use is presently under review by the US Food and Drug Administration (FDA). ResApp and Experien Group have provided detailed responses to all of questions received from the FDA to-date, and are working closely together to move the submission through the review.
- **First telehealth integration with CoviU.** In November, ResApp entered into a memorandum of understanding to integrate ResApp's acute respiratory diagnostic test, ResAppDx-EU into CoviU's browser-based telehealth platform. During the quarter ResApp's team has been working closely with CoviU and has made excellent progress towards having ResAppDx-EU available to the 5,500+ clinicians who currently use CoviU's platform.
- **Preparing regulatory submission for sleep apnoea.** Following the completion of the successful prospective at-home sleep apnoea study, ResApp has been preparing a CE Mark Technical File for an at-home obstructive sleep apnoea screening product. ResApp plans to complete the Technical File by the end of March 2020.



- **Continued progress under the Startup Creosphere program.** In October, ResApp announced that it had been selected to join the Startup Creosphere digital health program in Munich. During the program ResApp has been working closely with experts from Sanofi to explore opportunities to co-create consumer health-focused respiratory disease products. In November, ResApp granted the consumer healthcare business unit of Sanofi an exclusive option to license the outcomes generated under the Startup Creosphere incubator program. Sanofi has until the 7<sup>th</sup> of March to exercise the option. ResApp will present at the Startup Creosphere Expo Day in Munich on the 6<sup>th</sup> of February.
- **Received ethics approval for a clinical study of COPD in Indigenous Australians.** In December, ResApp received ethics approval for a pilot, double-blind study of its chronic obstructive pulmonary disease (COPD) screening smartphone application in an Indigenous Australian population. Indigenous Australians die from COPD at a rate 10 times greater than non-Indigenous Australians and it is the most common type of respiratory disease for which Indigenous Australians are hospitalised.
- **Strong balance sheet to advance ResApp through commercialisation.** The company held cash of \$3.9 million as of December 31, 2019. ResApp received a \$1.8 million R&D tax incentive cash rebate from its FY2019 R&D spend during the quarter. A significant proportion of R&D spend for the current financial year will also be eligible for the R&D tax incentive.

###

### About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional hardware. Clinical studies have demonstrated accurate diagnosis of lower respiratory tract disease, upper respiratory tract infection, pneumonia, bronchiolitis, croup, asthma exacerbation/reactive airway disease, chronic obstructive pulmonary disease, chronic obstructive pulmonary disease exacerbation and obstructive sleep apnoea. ResApp's smartphone-based acute respiratory disease diagnostic test, ResAppDx-EU, is CE Marked in the European Union and TGA approved in Australia. Potential customers of ResApp's products include healthcare providers in telehealth, emergency department, urgent care and primary care settings as well as humanitarian organisations in the developing world. For more information, visit [www.resapphealth.com.au](http://www.resapphealth.com.au).

### Contacts

Dr Tony Keating  
CEO and Managing Director  
+61 430 180 659  
[tony@resapphealth.com.au](mailto:tony@resapphealth.com.au)

Mr Brian Leedman  
Vice President, Corporate Affairs  
+61 412 281 780  
[brian@resapphealth.com.au](mailto:brian@resapphealth.com.au)

*This ASX announcement was approved and authorised for release by the board of directors of ResApp Health.*

## Appendix 4C

### Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

**Name of entity**

**ResApp Health Limited**

**ABN**

**51 094 468 318**

**Quarter ended ("current quarter")**

**31 December 2019**

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date (6 months) \$A'000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	-	56
1.2 Payments for		
(a) research and development	(778)	(1,406)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	(42)	(125)
(d) leased assets	-	-
(e) staff costs	(721)	(1,423)
(f) administration and corporate costs	(135)	(475)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	13	36
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	1,797	1,831
1.8 Other – R&D rebate	-	-
<b>1.9 Net cash from / (used in) operating activities</b>	<b>134</b>	<b>(1,506)</b>

<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire:		
(a) property, plant and equipment	(2)	(2)
(b) businesses (see item 10)	-	-
(c) investments	-	-

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date (6 months) \$A'000</b>
(d) intellectual property	-	-
(e) other non-current assets	-	(104)
<b>2.2 Proceeds from disposal of:</b>		
(a) property, plant and equipment	-	-
(b) businesses (see item 10)	-	-
(c) investments	-	-
(d) intellectual property	-	-
(e) other non-current assets	-	-
<b>2.3 Cash flows from loans to other entities</b>	-	-
<b>2.4 Dividends received (see note 3)</b>	-	-
<b>2.5 Other (provide details if material)</b>	-	-
<b>2.6 Net cash from / (used in) investing activities</b>	<b>(2)</b>	<b>(106)</b>

<b>3. Cash flows from financing activities</b>		
3.1 Proceeds from issues of shares	-	-
3.2 Proceeds from issue of convertible notes	-	-
3.3 Proceeds from exercise of share options	-	-
3.4 Transaction costs related to issues of shares, convertible notes or options	-	-
3.5 Proceeds from borrowings	-	-
3.6 Repayment of borrowings	-	-
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Other (provide details if material)	-	-
<b>3.10 Net cash from / (used in) financing activities</b>	<b>-</b>	<b>-</b>

<b>4. Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1 Cash and cash equivalents at beginning of quarter/year to date	3,772	5,516
4.2 Net cash from / (used in) operating activities (item 1.9 above)	134	(1,506)
4.3 Net cash from / (used in) investing activities (item 2.6 above)	(2)	(106)
4.4 Net cash from / (used in) financing activities (item 3.10 above)	-	-

<b>Consolidated statement of cash flows</b>		<b>Current quarter \$A'000</b>	<b>Year to date (6 months) \$A'000</b>
4.5	Effect of movement in exchange rates on cash held	-	-
<b>4.6</b>	<b>Cash and cash equivalents at end of quarter</b>	<b>3,904</b>	<b>3,904</b>

<b>5.</b>	<b>Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	<b>Current quarter \$A'000</b>	<b>Previous quarter \$A'000</b>
5.1	Bank balances	3,904	3,772
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>3,904</b>	<b>3,772</b>

<b>6.</b>	<b>Payments to directors of the entity and their associates</b>	<b>Current quarter \$A'000</b>
6.1	Aggregate amount of payments to these parties included in item 1.2	(116)
6.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	
6.3	Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2	
	<ol style="list-style-type: none"> <li>1. Director fees, salary and super; and</li> <li>2. Consultancy fees.</li> </ol>	

<b>7.</b>	<b>Payments to related entities of the entity and their associates</b>	<b>Current quarter \$A'000</b>
7.1	Aggregate amount of payments to these parties included in item 1.2	
7.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	
7.3	Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2	

<b>8. Financing facilities available</b> <i>Add notes as necessary for an understanding of the position</i>	<b>Total facility amount at quarter end \$A'000</b>	<b>Amount drawn at quarter end \$A'000</b>
8.1 Loan facilities	-	-
8.2 Credit standby arrangements	-	-
8.3 Other (please specify)	-	-
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		

--


<b>9. Estimated cash outflows for next quarter</b>	<b>\$A'000</b>
9.1 Research and development	(775)
9.2 Product manufacturing and operating costs	-
9.3 Advertising and marketing	(62)
9.4 Leased assets	-
9.5 Staff costs	(627)
9.6 Administration and corporate costs	(236)
9.7 Other (provide details if material)	-
<b>9.8 Total estimated cash outflows</b>	<b>(1,700)</b>

<b>10. Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)</b>	<b>Acquisitions</b>	<b>Disposals</b>
10.1 Name of entity	-	-
10.2 Place of incorporation or registration	-	-
10.3 Consideration for acquisition or disposal	-	-
10.4 Total net assets	-	-
10.5 Nature of business	-	-

### Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here:

  
.....  
(Director)

Date: 31<sup>st</sup> January 2020

Print name: Tony Keating

### Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.